The Priority Review

The stream · Daily digest

The stream: Thursday, October 22, 2026

9 briefs from ClinicalTrials.gov and FDA, grouped by desk. Each is two sentences from one primary source, linked to it.

Machine-summarized from primary sources; not independently reported. How we use automation

Clinical trials · 7

  1. Vertex registers Phase 3b study of Povetacicept vs Sibeprenlimab in Immunoglobulin A Nephropathy

    Vertex Pharmaceuticals Incorporated has registered a Phase 3b, open-label, single-arm study to evaluate participant experience with Povetacicept injection via autoinjector compared to Sibeprenlimab injection via prefilled syringe in adults with Immunoglobulin A Nephropathy. The study plans to enroll 40 participants, with a start date of October 23, 2026 and primary completion date of December 12, 2027.

    Source: ClinicalTrials.gov registry record, October 22, 2026

  2. Hoffmann-La Roche registers Phase III trial of enicepatide versus tirzepatide in type 2 diabetes

    The study, led by Hoffmann-La Roche with Chugai Pharmaceutical as collaborator, plans to enroll 948 participants and begin on December 1, 2026. It will evaluate the efficacy and safety of enicepatide, a glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor (GLP-1/GIP) receptor agonist (RA), compared with tirzepatide in participants with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on oral glucose-lowering medications.

    Source: ClinicalTrials.gov registry record, October 22, 2026

  3. Sanofi registers Phase 3 trial of combination SARS-CoV-2 and influenza vaccine in older adults

    The study, led by Sanofi, plans to enroll an estimated 6000 participants aged 60 and older to assess the safety and immunogenicity of a combined SARS-CoV-2 recombinant spike and high-dose inactivated influenza vaccine with Matrix-M adjuvant. It is planned to begin on November 9, 2026, with primary completion expected on December 28, 2027.

    Source: ClinicalTrials.gov registry record, October 22, 2026

  4. Pfizer registers Phase 3 trial of atirmociclib plus giredestrant in ER+ HER2- early breast cancer

    The study plans to enroll 3800 participants and randomize them 1:1 to receive atirmociclib plus giredestrant or placebo plus giredestrant. It is scheduled to begin on December 1, 2026, with a primary completion date of April 13, 2032.

    Source: ClinicalTrials.gov registry record, October 22, 2026

  5. ScandiBio registers Phase 3 trial of CMA2 in gout

    The study plans to enroll 336 participants and is expected to start in October 2026, with primary completion projected for February 2027. This will be a randomised, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, and tolerability of Combined Metabolic Activator (CMA2) including N-acetyl-L-cysteine, L-carnitine-L-tartrate, nicotinamide, and L-serine versus placebo.

    Source: ClinicalTrials.gov registry record, October 22, 2026

  6. Merck posts results of Phase III KEYNOTE-522 trial in triple negative breast cancer

    The study enrolled 1,174 participants and compared pembrolizumab plus chemotherapy to placebo plus chemotherapy as neoadjuvant therapy, followed by pembrolizumab or placebo as adjuvant therapy. Results were first posted on ClinicalTrials.gov on October 22, 2026.

    Source: ClinicalTrials.gov results record, October 22, 2026

  7. Medtronic reports positive real-world registry results for Sphere-9 and PulseSelect at APHRS 2026

    Medtronic said the APEX registry included 1,050 patients with atrial fibrillation treated with the Sphere-9 catheter, reporting a 1.1% major complication rate. The REAL PULSE registry included 1,160 patients and reported a 100% acute success rate with a 0.09% acute major complication rate.

    Source: Company press release (PR Newswire), October 22, 2026

Approvals · 1

  1. FDA grants traditional approval for pembrolizumab and Keytruda QLEX for TMB-H solid tumors

    On October 16, 2026 the FDA granted traditional approval to pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmh (Keytruda QLEX) for patients with unresectable or metastatic tumor mutational burden-high (TMB-H) solid tumors defined as ≥13 mutations/megabase. In the KEYNOTE-158 study, 220 patients with TMB ≥13 mut/Mb had an objective response rate of 36% (95% CI: 30, 43) and 58% achieved a duration of response of at least 12 months.

    Source: FDA approval notification, October 22, 2026

Policy · 1

  1. Lilly breaks ground on $5 billion Richmond facility to produce API and finished medicines

    Eli Lilly and Company announced on Oct. 22, 2026 that it broke ground on a $5 billion manufacturing facility just west of Richmond, Virginia, the company's first fully integrated site to produce both active pharmaceutical ingredients and finished antibody-drug conjugates. The new plant is expected to create 650 high-wage jobs and about 1,800 construction jobs during construction.

    Source: Company press release (PR Newswire), October 22, 2026